Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02285192 · ClinicalTrials.gov registry record · Phase 1
Positron Lymphography Via Intracervical 18F-FDG Injection for Pre-surgical Lymphatic Mapping in Stage IB1 Cervical Cancer and High-grade Endometrial Cancer
A Phase 1 study of Endometrial Cancer and Cervical Cancer, sponsored by Memorial Sloan Kettering Cancer Center.
- Active
- Registry status
- Phase 1
- Development phase
- 42
- Enrollment target
- 7
- Study locations
NCT02285192: Active Phase 1 study of Endometrial Cancer and Cervical Cancer, sponsored by Memorial Sloan Kettering Cancer Center.
NCT02285192 is a Phase 1 study of Endometrial Cancer and Cervical Cancer that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 42 participants, below the 524-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (92% lower). The trial reports 7 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02285192, a Phase 1 study of Endometrial Cancer and Cervical Cancer, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 42 participants
- Enrollment target
- 7
- Study locations
Study Summary
The purpose of this study is to see if a radioactive substance called 18F-Fluorodeoxyglucose (18F- FDG), injected into the cervix during a PET/CT scan done before surgery can show us more clearly which lymph nodes in the pelvis (the area near your uterus and cervix) contain cancer.
Primary Outcome
Accuracy of Positron Lymphography will be defined in terms of sensitivity and will consist of pathology review of labelled, excised specimens compared with lymph node imaging data acquired preoperatively.
Conditions Studied
Interventions
- DEVICE PET/CT imaging
- RADIATION 18F-Fluorodeoxyglucose (18F-FDG)
- DEVICE PET/MRI imaging
Study Locations (7)
New York
- Memorial Sloan Kettering Commack (Consent only) - Commack
- Memorial Sloan Kettering Westchester (Consent only) - Harrison
- Memorial Sloan Kettering Cancer Center - New York
- Memorial Sloan Kettering Nassau (Consent only) - Uniondale
New Jersey
- Memorial Sloan Kettering Basking Ridge (Consent only) - Basking Ridge
- Memorial Sloan Kettering Monmouth (Consent only) - Middletown
- Memorial Sloan Kettering Bergen (Consent only) - Montvale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2014-11 |
| Est. Completion | 2026-11 |
| Phase | Phase 1 |
What the registry record for NCT02285192 still lists
NCT02285192 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 42 participants, a relatively small participant target, below the 524-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (92% lower).
The record links to 2 conditions, with Endometrial Cancer appearing as the primary indexed condition, and to 3 interventions - of which PET/CT imaging is the first listed.
NCT02285192 lists 7 locations in 2 states (New York, New Jersey).
Frequently Asked Questions
What is clinical trial NCT02285192 about?
NCT02285192 is a clinical study titled "Positron Lymphography Via Intracervical 18F-FDG Injection for Pre-surgical Lymphatic Mapping in Stage IB1 Cervical Cancer and High-grade Endometrial Cancer". The purpose of this study is to see if a radioactive substance called 18F-Fluorodeoxyglucose (18F- FDG), injected into the cervix during a PET/CT scan done before surgery can show us more clearly which lymph nodes in the pelvis (the area near your uterus and cervix) contain cancer.
What is the current status of trial NCT02285192?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2014-11. Estimated completion is 2026-11.
What conditions does trial NCT02285192 study?
This clinical trial studies the following conditions: Endometrial Cancer, Cervical Cancer.
What interventions are being tested in trial NCT02285192?
The interventions under investigation include: PET/CT imaging (DEVICE), 18F-Fluorodeoxyglucose (18F-FDG) (RADIATION), PET/MRI imaging (DEVICE).
Who is sponsoring clinical trial NCT02285192?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02285192 being conducted?
This trial has 7 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Endometrial Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02285192's enrollment target sits among peer trials
42 135th of 181 higher than 46 of 181 other Endometrial Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Endometrial Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
RECRUITING · Phase 1
-
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of AVZO-021 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer
RECRUITING · Phase 1
-
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02852213 · 42 participants · Phase 1
A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients
- NCT03136146 · 42 participants · Phase 2
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
- NCT03178149 · 42 participants · Phase 1
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
- NCT03663530 · 42 participants · NA
Circadian Misalignment and Energy Balance
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia